Results 141 to 150 of about 19,613 (205)

Multimodality Imaging in Hypertrophic Cardiomyopathy. [PDF]

Card Fail Rev
Escribano D, Díaz-Peláez E, Delgado V.
europepmc   +1 more source

Mechanisms and biomarkers of immune checkpoint inhibitor-associated myocarditis: from T cell imbalance to multicellular crosstalk. [PDF]

Front Immunol
Huang J, Xu X, Jin Y, Qiao L, Yu H, Gao W, Li C.   +6 more
europepmc   +1 more source

Evolving strategies in obstructive hypertrophic cardiomyopathy: myosin inhibitors as monotherapy compared with beta-blockers. [PDF]

Heart Fail Rev
Grupper A, Sverdlov AL, Cheema BS, Nasrollahizadeh A, Hosseini K.   +4 more
europepmc   +1 more source

The Dawn of a New Era in Hypertrophic Cardiomyopathy. [PDF]

Acta Cardiol Sin
Yu WC.
europepmc   +1 more source

Understanding immune checkpoint inhibitors-related myocarditis: Mechanisms and targeted therapeutic pathways. [PDF]

Theranostics
Xia W, Zhang H, Liu L, Tu C, Song X.
europepmc   +1 more source

Mavacamten in Obstructive Hypertrophic Cardiomyopathy and C282Y Homozygous Hereditary Hemochromatosis: A First-in-Human Report. [PDF]

JACC Case Rep
Sam R, Ananthaneni A, Planek MI, Kogan A, Gordon R.   +4 more
europepmc   +1 more source

Pharmacologic therapies for hypertrophic cardiomyopathy: The past, the present, and the future. [PDF]

JRSM Cardiovasc Dis
Halațiu VB, Cozac DA, Scridon A.
europepmc   +1 more source

RoMa Classification: When the Parts Do Not Equal the Sum. [PDF]

J Am Heart Assoc
MacNamara JP, Angadi SS.
europepmc   +1 more source

Single-cell transcriptomic insights into the immune heterogeneity of immune checkpoint inhibitors related organ toxicities. [PDF]

Front Immunol
Wen H, Qi Y, Song J, Yan X.
europepmc   +1 more source

Best practices in specialized hypertrophic cardiomyopathy centers in the United States: a survey of cardiologists, nurses, pharmacists, patients, and patient advocates. [PDF]

Future Cardiol
Maron M, Steeves B, Wang A.
europepmc   +1 more source